Shots:

• The P-III (DELIVER) trial evaluating Farxiga (qd) + SoC vs PBO in 6263 patients with HF with LVEF ≥40% with/out T2D
• The results showed an improvement in symptom burden and health-related QoL in patients with HF and mildly reduced or preserved EF, clinical benefits were observed, and benefits were sustained @8mos. with a mean improvement in total symptom score. The results were presented at AHA 2022 & published in the JACC
• Patients achieved a significant deterioration, improvements in health status across evaluated KCCQ domains, and benefits of Farxiga on CV death & worsening HF. The safety & tolerability profiles were consistent with the well-established safety profile of the therapy

Ref: AstraZeneca | Image: AstraZeneca